Results 51 to 60 of about 13,819 (183)

Candida vulturna, the Next Fungal Menace? A Narrative Review

Mycoses, Volume 68, Issue 5, May 2025.
ABSTRACT Introduction The yeast Candida vulturna is a member of the Candida haemulonii species complex, like its close relative Candida auris. Members of this species complex, including C. vulturna, often display reduced susceptibility to one or more antifungal classes. Human invasive infections by C.
Ritika Harchand, Bram Spruijtenburg, Eelco F. J. Meijer, Theun de Groot, Shivaprakash M. Rudramurthy, Jacques F. Meis   +5 more
wiley   +1 more source

Efficacy of Low‐Dose Fluconazole for Primary Prophylaxis of Invasive Candida Infections in Patients With Acute Leukemia: A Double‐Blind Randomized Clinical Trial

Cancer Medicine, Volume 14, Issue 7, April 2025.
ABSTRACT Background Invasive fungal infections (IFIs), particularly Candida infections, are a significant cause of morbidity and mortality in patients with acute leukemia. While fluconazole is widely used for prophylaxis, the optimal dosing regimen remains uncertain.
Roghayeh Savary‐Kouzehkonan, Kourosh Sadeghi, Soroush Rad, Neda Alijani, Zohreh Baseri, Mohammad Vaezi, Seyed Asadollah Mousavi, Bita Shahrami   +7 more
wiley   +1 more source

Development of UPLC-MS/MS Method for Studying the Pharmacokinetic Interaction Between Dasatinib and Posaconazole in Rats

Drug Design, Development and Therapy, 2021
Suili Yang,1,* Xiaoshan Zhang,2,3,* Yuzhen Wang,2,3 Congcong Wen,4 Chenxiang Wang,3 Ziye Zhou,5 Guanyang Lin3 1Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China ...
Yang S, Zhang X, Wang Y, Wen C, Wang C, Zhou Z, Lin G   +6 more
doaj  

Invasive Fungal Disease Associated With Targeted Agents for Acute Myeloid Leukaemia: A Systematic Review

eJHaem, Volume 6, Issue 2, April 2025.
ABSTRACT Objective To examine the incidence of invasive fungal disease (IFD) in patients receiving targeted agents for acute myeloid leukaemia (AML). Methods Literature for this systematic review was identified through a PubMed search in April 2024, using AML, IFD and targeted therapy terms.
Samir Agrawal, Anjaneya Bapat, Christopher P. Eades, Shreyans Gandhi   +3 more
wiley   +1 more source

The use of posaconazole delayed-release tablets in the successful treatment of suspected mucormycosis in a bottlenose dolphin (Tursiops truncatus) calf

Medical Mycology Case Reports, 2021
Mucorales infections in cetaceans have a high mortality rate. This case report refers to a bottlenose dolphin calf with suspected mucormycosis treated with posaconazole.
Gonçalo N. Marques, Nuno U. Silva, Miriam O. Leal, Carla A. Flanagan   +3 more
doaj  

Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen

European Journal of Haematology, Volume 114, Issue 4, Page 626-635, April 2025.
ABSTRACT Venetoclax with hypomethylating agents (HMA) is the standard of care for acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy and is associated with tumor lysis syndrome (TLS). TLS prophylaxis and the use of Cairo Bishop versus Howard diagnostic criteria are not standardized.
Margaret Rowe, Daria Babushok, Martin Carroll, Alison Carulli, Noelle Frey, Saar Gill, Elizabeth Hexner, Rebecca Hirsh, Nasheed Hossain, Catherine Lai, Alison Loren, Selina Luger, Ivan Maillard, Shannon McCurdy, Andrew Matthews, Mary Ellen Martin, Vikram R Paralkar, Alexander Perl, David Porter, Keith Pratz, Edward Stadtmauer, Ximena Jordan Bruno   +21 more
wiley   +1 more source

Enhanced antifungal activity of posaconazole against Candida auris by HIV protease inhibitors, atazanavir and saquinavir

Scientific Reports
The increasing incidence and dissemination of multidrug-resistant Candida auris represents a serious global threat. The emergence of pan-resistant C. auris exhibiting resistance to all three classes of antifungals magnifies the need for novel therapeutic
Yehia Elgammal, Ehab A. Salama, Mohamed N. Seleem   +2 more
doaj   +1 more source

A Review of Population Pharmacokinetic Models of Posaconazole

Drug Design, Development and Therapy, 2022
Qin Ding,1,* Shuqi Huang,1,* Zexu Sun,2 Kaifeng Chen,1 Xin Li,3 Qi Pei1 1Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, People’s Republic of China; 2Xiangya School of Pharmaceutical Sciences, Central South
Ding Q, Huang S, Sun Z, Chen K, Li X, Pei Q   +5 more
doaj  

Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents

Therapeutic Advances in Hematology, 2020
Background: Although many acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients have been treated with hypomethylating agents (HMAs) as a substitute for intensive chemotherapy in recent years, the incidence of invasive fungal ...
Ka-Won Kang, Byung-Hyun Lee, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Yong Park, Byung Soo Kim   +9 more
doaj   +1 more source

Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery.

PLoS Neglected Tropical Diseases, 2018
Chagas' disease is responsible for significant mortality and morbidity in Latin America. Current treatments display variable efficacy and have adverse side effects, hence more effective, better tolerated drugs are needed.
Lorna M MacLean, John Thomas, Michael D Lewis, Ignacio Cotillo, David W Gray, Manu De Rycker   +5 more
doaj   +1 more source